Emotion Regulation Intervention for Autism, Early Infantile

Phase-Based Progress Estimates
Institute of Living, Hartford Hospital, Hartford, CT
Autism, Early Infantile+1 More
Emotion Regulation Intervention - Behavioral
18 - 65
All Sexes
What conditions do you have?

Study Summary

This pilot study is designed to investigate the clinical outcomes and neural mechanisms of emotion regulation behavioral treatment , in a small sample of young adults diagnosed with autism spectrum disorder.

Eligible Conditions

  • Autism, Early Infantile

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Autism, Early Infantile

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 2 months follow-up

2 months follow-up
Adult Behavior Checklist (ABC-L)
Adult Self Report (ASR)

Trial Safety

Safety Progress

1 of 3

Other trials for Autism, Early Infantile

Trial Design

1 Treatment Group

ER intervention
1 of 1
Experimental Treatment

5 Total Participants · 1 Treatment Group

Primary Treatment: Emotion Regulation Intervention · No Placebo Group · N/A

ER intervention
Experimental Group · 1 Intervention: Emotion Regulation Intervention · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 months follow-up
Closest Location: Institute of Living, Hartford Hospital · Hartford, CT
Photo of connecticut 1Photo of connecticut 2Photo of connecticut 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Autism, Early Infantile
0 CompletedClinical Trials

Who is running the clinical trial?

Michal AssafLead Sponsor

Eligibility Criteria

Age 18 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a T score of 60 or higher on either the externalizing or internalizing symptoms scores of either the Adult Behavior Checklist (ABC-L) or the Adult Self Report (ASR).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.